Leveraging Dysregulated Signaling Networks for Therapeutic Benefit in Myeloid Malignancies | VuMedi

Icahn School of Medicine at Mount Sinai

Leveraging Dysregulated Signaling Networks for Therapeutic Benefit in Myeloid Malignancies

By Icahn School of Medicine at Mount Sinai FEATURING Stephen Oh

By Icahn School of Medicine at Mount Sinai FEATURING Stephen Oh

0 views

July 2, 2024

Comments 0

Login to view comments. Click here to Login